Crescent Biopharma Announces Grants of Inducement Awards

Rhea-AI Summary

Crescent Biopharma (Nasdaq: CBIO) reported that the independent Compensation Committee of its Board approved equity inducement awards consisting of options to purchase an aggregate of 52,500 ordinary shares for two non-executive employees under the 2025 Employment Inducement Incentive Award Plan. The options were approved on July 22, 2026, have a 10-year term, and an exercise price of $15.83, equal to the closing price of Crescent’s shares on that date. According to Crescent Biopharma, each grant vests 25% on the first anniversary of the employee’s start date, with the remaining 75% vesting in equal monthly installments over the following three years, subject to continuous service and the terms of the Inducement Plan and individual option agreements.

Argus Jul 24 session 10 alerts

-4.29% close to close 0.4x rel. volume Open Argus

Details

Market reaction after inducement award grants: CBIO -4.29% in the Jul 24 session

+4.4% Peak Tracked

-3.7% Trough Tracked

$615.06M Market Cap

In the Jul 24 session, CBIO declined 4.29%, reflecting a moderate negative market reaction. Argus tracked a peak move of +4.4% during that session. Argus tracked a trough of -3.7% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The June 26 inducement-award announcement was followed by a -3.02% 24-hour reaction, while the June ...

Analysis

The June 26 inducement-award announcement was followed by a -3.02% 24-hour reaction, while the June 11 counterpart was followed by 0.57%. The current grant terms add no operating results; the active S-3 shelf and high short positioning remain relevant context.

Key Figures

Aggregate Options: 52,500 shares Recipients: 2 employees Approval Date: July 22, 2026 +4 more

Aggregate Options

52,500 shares

Granted to two non-executive employees

Recipients

2 employees

Non-executive employees receiving inducement awards

Approval Date

July 22, 2026

Date options were approved

Option Term

10 years

Term of each granted option

Exercise Price

$15.83

Equal to the July 22, 2026 Nasdaq closing price

Initial Vesting

1/4 of shares

Vests on the first anniversary of each employee’s start date

Subsequent Vesting

1/48 of shares monthly

Vests monthly after the first anniversary, subject to continuous service

Historical Context

5 past events · Latest: Jul 16

5 events

1. Jul 16

   Public offering closing

   24h Move

   -2.4%

   Offering closed with newly issued shares and pre-funded warrants totaling approximately $143.7 million gross proceeds

2. Jul 14

   Public offering pricing

   24h Move

   +2.4%

   Company priced ordinary shares and pre-funded warrants in an underwritten public offering

3. Jul 14

   Public offering launch

   24h Move

   +2.4%

   Company commenced an underwritten offering under an effective Form S-3 shelf registration

4. Jun 26

   Inducement award grants

   24h Move

   -3.0%

   Stock options covering 65,100 shares were granted to three non-executive employees

5. Jun 11

   Inducement award grants

   24h Move

   +0.6%

   Stock options covering 23,550 shares were granted to two non-executive employees

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

equity inducement awards, nasdaq listing rule 5635(c)(4), exercise price, vesting

4 terms

equity inducement awards financial

"approved the grant of options to purchase an aggregate of 52,500 shares"

Equity inducement awards are special stock-based rewards given to new employees to encourage them to join a company or stay long-term. They are like signing bonuses paid with company shares instead of cash, helping motivate employees to contribute to the company's success.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

exercise price financial

"an exercise price equal to $15.83"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"shall vest and become exercisable as to one-fourth"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 52,500 shares of the Company’s ordinary shares to two non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). The options were approved on July 22, 2026 and were material to each employee's acceptance of employment with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4).

The options were granted with a 10-year term and an exercise price equal to $15.83, the closing price per share of Crescent’s ordinary shares as reported by Nasdaq on July 22, 2026. The options granted to each employee shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Crescent through the applicable vesting dates. The options are subject to the terms of the Inducement Plan and the terms and conditions of an option agreement covering the applicable grant.

About Crescent Biopharma 

Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X. 

Contacts

Investors

Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586

Media

Jenna Poist
Director, Corporate Communications
jenna.poist@crescentbiopharma.com
781-671-5019

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity inducement awards did Crescent Biopharma (CBIO) grant on July 22, 2026?

Crescent Biopharma granted options to purchase an aggregate of 52,500 ordinary shares to two non-executive employees. According to Crescent Biopharma, these were equity inducement awards under its 2025 Employment Inducement Incentive Award Plan, approved by the Board’s Compensation Committee.

What is the exercise price and term of Crescent Biopharma (CBIO) inducement stock options?

The inducement stock options have an exercise price of $15.83 per share and a 10-year term. According to Crescent Biopharma, the price equals the July 22, 2026 Nasdaq closing price of its ordinary shares.

How do the Crescent Biopharma (CBIO) inducement options vest for the new employees?

The options vest 25% on the first anniversary of each employee’s start date, then monthly thereafter. According to Crescent Biopharma, one-forty-eighth of the shares vest monthly over the remaining three years, subject to continuous service.

Why were the Crescent Biopharma (CBIO) stock options granted as inducement awards?

The options were granted as equity inducement awards material to each employee’s acceptance of employment. According to Crescent Biopharma, the grants comply with Nasdaq Listing Rule 5635(c)(4) under its 2025 Employment Inducement Incentive Award Plan.

How many Crescent Biopharma (CBIO) shares are covered by each employee’s inducement option grant?

Crescent Biopharma granted options over an aggregate of 52,500 shares to two employees, implying each received a portion of this total. According to Crescent Biopharma, all options are granted under the 2025 Employment Inducement Incentive Award Plan.

What conditions apply to exercising Crescent Biopharma (CBIO) inducement stock options?

The options must be vested and are exercisable within a 10-year term at $15.83 per share. According to Crescent Biopharma, vesting requires continuous service and is subject to the Inducement Plan and individual option agreements.